Trial reportObesity (Silver Spring, Md.)2017
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Trial report in Obesity (Silver Spring, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The weight reducing effects of naltrexone-bupropion among obese psychiatric and non-psychiatric patients: a systematic review.Psychopharmacology · 2025Pooled it
- Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool.Nutrients · 2023Pooled it
- Characterization of the effect of naltrexone/bupropion on body composition.Diabetes, obesity & metabolism · 2025Trial
- Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.JAMA network open · 2022Trial
- Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care.Obesity pillars · 2025Review
- Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience.Endocrine · 2025Article
- Review
- The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy.EClinicalMedicine · 2022Article
- Long-Term Weight Loss Strategies for Obesity.The Journal of clinical endocrinology and metabolism · 2021Review
- Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review.Archives of medical science : AMS · 2021Review
- Central nicotine induces browning through hypothalamic κ opioid receptor.Nature communications · 2019Article
- Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion.Obesity science & practice · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks.
methodsIn this phase 3b, randomized, open-label, controlled study, subjects received NB + CLI or usual care (standard diet/exercise advice) for 26 weeks. NB subjects not achieving 5% weight loss at week 16 were discontinued, as indicated by product labeling. After week 26, usual care subjects began NB + CLI. Assessments continued through week 78. The primary end point was percent change in weight from baseline to week 26 in the per protocol population. Other end points included percentage of subjects achieving ≥5%, ≥10%, and ≥15% weight loss, percent change in weight at week 78, and adverse events (AEs) necessitating study medication discontinuation.
resultsNB + CLI subjects lost significantly more weight than usual care subjects at week 26 (8.52% difference; P < 0.0001). Weight loss persisted through 78 weeks. In total, 20.7% of subjects discontinued medication for AEs, including 7.0% for nausea.
conclusionsTreatment with NB, used as indicated by prescribing information and with CLI, significantly improved weight loss over usual care alone. NB-facilitated weight loss was sustained for 78 weeks and was deemed safe and well tolerated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.